Amylyx Donates CENTAUR Trial Data to PRO-ACT Database for ALS
Amylyx Pharmaceuticals has donated data from the CENTAUR Phase 2 trial to the PRO-ACT database — the largest collection ever…
Articles by Lindsey Shapiro, PhD
Engensis Gene Therapy Found Safe in Small Phase 2a Trial
Repeated muscle injections with Engensis (VM202), Helixmith’s investigational non-viral gene therapy, were generally safe and well-tolerated in people with…
Whole-genome Sequencing Provides ALS Genetic Architecture ‘Snapshot’
Whole-genome sequencing, a type of genetic screening that examines a person’s complete DNA sequence, may be a promising way to…
Amydis Developing Test to Measure TDP-43 Biomarker in Eye’s Retina
Amydis is developing a test to monitor the buildup of TDP-43 in the eye’s retina of people with…
Initiative Makes Stem Cell Lines Available for Research Worldwide
A number of stem cell lines developed to better understand how certain genetic factors might contribute to amyotrophic lateral…
Radicava Seen in Real-world Study to Prolong Survival With ALS
Real-world use of Radicava (edaravone) significantly prolongs survival in amyotrophic lateral sclerosis (ALS) patients, with people in the U.S.
Long-term Radicava Safe, Modestly Effective in Small Korean Study
Long-term use of Radicava (edaravone) is safe and may modestly slow disease progression in people with amyotrophic lateral…
NOVA1 Protein May Be Involved in Early ALS Disease Mechanisms
A protein called NOVA1 may be involved in the early disruption of protein production in amyotrophic lateral sclerosis (ALS),…
Amylyx, Sunnybrook Partner to Find New ALS Therapeutics
Amylyx Pharmaceuticals has partnered with Sunnybrook Research Institute (SRI) to find new therapeutic candidates for amyotrophic lateral sclerosis…
FDA Panel Reconvenes in September to Discuss AMX0035 Approval
A U.S. Food and Drug Administration (FDA) advisory committee will meet  Sept. 7 to discuss the approval of AMX0035…